Detalles de la búsqueda
1.
Patient factors influencing acute gluten reactions and cytokine release in treated coeliac disease.
BMC Med
; 18(1): 362, 2020 11 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-33239013
2.
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study.
Lancet Gastroenterol Hepatol
; 8(5): 446-457, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36898393
3.
A Sensitive Whole Blood Assay Detects Antigen-Stimulated Cytokine Release From CD4+ T Cells and Facilitates Immunomonitoring in a Phase 2 Clinical Trial of Nexvax2 in Coeliac Disease.
Front Immunol
; 12: 661622, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34093551
4.
Masked bolus gluten challenge low in FODMAPs implicates nausea and vomiting as key symptoms associated with immune activation in treated coeliac disease.
Aliment Pharmacol Ther
; 51(2): 244-252, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31769533
5.
Elevated serum interleukin-2 after gluten correlates with symptoms and is a potential diagnostic biomarker for coeliac disease.
Aliment Pharmacol Ther
; 50(8): 901-910, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31483515
6.
New Clinical-Pathological Classification of Intraspinal Injury Following Traumatic Acute Complete Thoracic Spinal Cord Injury: Postdurotomy/Myelotomy Observations From the INSPIRE Trial.
Neurosurgery
; 64(CN_suppl_1): 105-109, 2017 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28899037
Resultados
1 -
6
de 6
1
Próxima >
>>